The Organizing Committee deeply thanks 17-ICML reviewers and Advisory Board members for their collaboration and expertise: their contribution was essential to the program definition.
These sessions offer participants an opportunity to discuss clinical cases that they encounter on a day-to-day basis in their work as lymphoma specialists but for which there might be no clearly defined best practices.
Each of the five sessions (Aggressive NHL, Indolent NHL and CLL, HL and T-Cell Lymphomas, Difficult Pathological Cases, Paediatric Lymphomas) will involve world-renowned specialists who will bring their knowledge and expertise to the benefit of our participants.
HL and T-Cell Lymphomas
Presenter: Alden Moccia, Bellinzona (CH)
Discussants: Richard Hoppe, Stanford, CA (US), Andrew Lister, London (UK) - Chair - and Astrid Pavlovsky, Buenos Aires (AR)
Indolent NHL and CLL
Presenter: Adalgisa Condoluci, Bellinzona (CH)
Discussants: Jonathan Friedberg, Rochester, NY (US) - Chair -, Mary Gospodarowicz, Toronto, ON (CA) and Michael Hallek, Cologne (DE)
Aggressive NHL
Presenter: Maria Cristina Pirosa, Bellinzona (CH)
Discussants: John Leonard, New York, NY (US) - Chair - and Catherine Thieblemont, Paris (FR)
Difficult pathological cases
Presenters: Luca Mazzucchelli, Locarno (CH) - Chair - and Emanuele Zucca, Bellinzona (CH)
Discussants: Stephan Dirnhofer, Basel (CH) and Leticia Quintanilla - Martinez, Tuebingen (DE)
Paediatric Lymphomas
Presenter: Francesco Ceppi, Lausanne (CH)
Wilhelm Wössmann, Hamburg (DE) - Chair
Two Educational symposia will take place in parallel on Wednesday morning before the official opening of the Conference. Each symposium will extensively address a specific topic, explained in 3 lectures (20 minutes each) by experts who will explore and scrutinize different aspects of the chosen topics. Attendees will have the possibility to ask questions to the speakers and ample time will devoted also to the discussion among the experts.
Diffuse large B-cell lymphomas (DLBCL)
Lecture 1: CAR T-cells: Gilles Salles, New York, NY (USA) - Chair
Lecture 2: Bispecific antibodies: Martin Hutchings, Copenhagen (Denmark)
Lecture 3: New agents: Ranjana H. Advani, Stanford, CA (USA)
Chronic lymphocytic leukemia (CLL)
Lecture 1: Biology: Nicholas Chiorazzi, Manhasset, NY (USA)
Lecture 2: First line therapy: Michael Hallek, Cologne (Germany) - Chair
Lecture 3: Therapy of relapsed disease and Richter's syndrome: John F. Seymour, Melbourne (Australia)
These sessions are simultaneous sessions highlighting abstracts of scientific value that have not been selected for oral presentations during the general sessions. These sessions run in parallel and each session focuses on a particular topic. Each one-hour session consists of 6 presentations of 10 minutes each, including discussions and Q&A.
These sessions have been defined on the basis of abstract evaluation.
Based on the abstracts received and accepted for oral presentations, general sessions are devoted either to specific subtypes of lymphoid neoplasia (e.g. mantle cell lymphomas, follicular lymphomas, T-cell lymphomas, etc) or to the presentation of laboratory and clinical research data grouped around a biologic topic (e.g. microenvironment, signaling pathway, surface antigens).
On May 30th, 2023, the Late Breaking Abstracts session has been defined and is now available in the 17-ICML Scientific Program.
The program also includes two sessions devoted entirely to basic and translational research topics ("Dissecting lymphomas at the single cell level" and "Epigenetic mechanisms and targeted therapies in B- and T-cell lymphomas”).
Two abstracts related to these topics have been selected for presentation during these two sessions.
AACR-ICML joint session: "Technology that will change lymphoma understanding and care"
The AACR-ICML joint session will discuss how the development of novel technologies has already positively impacted the research field and how new tools based on them are entering the clinical context. The session includes applications of next-generation sequencing (NGS) for the study of the neoplastic and non-neoplastic cells within tumors at the single cell level and for the analysis of the circulating tumor DNA to obtain a comprehensive and dynamic picture of all the tumor cells in an individual patient. The final talk of the session will present how artificial intelligence (AI) can help us in the clinical development of novel therapies.
Co-chairs: Francesco Bertoni, Bellinzona (CH) and Margaret Foti, Philadelphia, PA (USA)
1) Single cell analysis: Katia Basso, New York, NY (USA)
2) Circulating tumor DNA (liquid biopsy): Davide Rossi, Bellinzona (Switzerland)
3) Organoids: Arianna Baggiolini, Bellinzona (Switzerland)
ESMO-ICML joint lecture
Does it matter how we name lymphomas - what’s in a name?
James O. Armitage, Omaha, NE (USA)
UCLI-ICML joint session: “Lymphoma research: news from China and Europe"
We are very pleased to see that Chinese lymphoma colleagues have once again come to ICML. The UCLI-ICML forum will be held on June 16, 2023. The theme of the forum is "Lymphoma Research: News from China and Europe". Lymphoma specialists from UCLI and ICML will present special reports on the new progress of lymphoma research in China and Europe. We welcome experts from all over the world to participate in this forum to discuss the development of lymphoma research.
Honorary co-chairs: Jun Ma, Harbin (China), Jun Zhu, Beijing (China), Franco Cavalli, Bellinzona (Switzerland) and Julie Vose, Omaha, NE (USA)
Executive co-chairs: Yuqin Song, Beijing (China), Junning Cao, Shanghai (China), Emanuele Zucca, Bellinzona (Switzerland) and Laurence De Leval, Lausanne (Switzerland)
1) Introduction of Lymphoma Database of National Health Commission of the People's Republic of China: Weiping Liu, Beijing (China)
2) History and achievements of International Extranodal Lymphoma Study Group (IELSG): Emanuele Zucca, Bellinzona (Switzerland)
3) Smart start with Tislelizumab as the frontline treatment in patients with high-risk stage IIB and advanced stage classical Hodgkin Lymphoma: Zhiming Li, Guangzhou (China)
4) Role of checkpoint inhibitor in Germany: Peter Borchmann, Cologne (Germany)
5) New drug development in lymphoma of China is going global: Keshu Zhou, Zhengzhou (China)
6) New trends in lymphoma treatment in Western Countries: Pier Luigi Zinzani, Bologna (Italy)
The Keynotes lectures are among the most significant moments of the Congress and are dedicated to three prominent individuals engaged in the study of lymphomas, in the development of therapeutic strategies targeting lymphomas and in particular, those recognised for their important contributions throughout the history of the ICML. These lectures are assigned to distinguished scientists and researchers by the Organizing Committee, with the help of the Advisory Board, on the basis of various criteria.
“Henry Kaplan Memorial Lecture”
This celebrates the achievements of a lifetime career and acknowledges the activity that has led to significant and appreciated results over the years.
Henry Kaplan was a pioneer in the study and treatment of lymphomas and inspired the choice of Lugano as venue for the ICML.
The 2023 Lecture is linked to the San Salvatore Foundation Prize.
“Lessons Learned from the Genetic Heterogeneity of Lymphoid Malignancies”: Margaret A. Shipp, Boston, MA (USA)
Wednesday, June 14, Room A Palazzo dei Congressi
“Gianni Bonadonna Memorial Lecture”
This covers topics particularly important for translational research and marks our collaboration with the European School of Oncology (ESO).
Gianni Bonadonna developed what has become the standard therapy for Hodgkin lymphoma (ABVD), which has maintained its importance for decades and he was one of the 3 oncologists who first decided to dedicate a congress entirely to malignant lymphomas.
“Elucidating the enigmatic pathobiology of Hodgkin lymphoma”: Ralf Küppers, Essen (Germany)
Thursday, June 15, Room A Palazzo dei Congressi
“John Ultmann Memorial Lecture”
This deals with clinical topics and is organized in collaboration with the American Association for Cancer Research (AACR).
John Ultmann was a pioneer in the precise staging of Hodgkin's disease and its application as a guide for treatment. He was a member of the ICML Organizing Committee from its first edition until the year of his death in 2000.
“25 years of antibody treatments for lymphoma”: Peter W.M. Johnson, Southampton (GB)
Friday, June 16, Room A Palazzo dei Congressi
“Meet the Professor” sessions are 45-minutes lessons (30 minutes frontal lecture and 15 minutes discussion) that allow participants to meet internationally recognized experts and gain a deeper insight into topics of particular interest.
Out of 12 sessions, 8 are repeated twice and 4 are offered only once.
No registration is required but early arrival is recommended to ensure the possibility to enter the halls (participation is subject to availability of seats).
- Advances in PET and radiomics
Sally Barrington, London (UK) - Cutaneous T-cell lymphomas – focus on some problems and some solutions
Helmut Beltraminelli, Locarno (Switzerland) - Management of Primary and Secondary CNS Lymphoma
Kate Cwynarski, London (UK) - Mantle cell lymphomas
Martin Dreyling, Munich (Germany) - Update on follicular lymphomas
Jonathan W. Friedberg, Rochester, NY (USA) - Post-transplantation lymphoproliferative disorders in children (PTLD)
Thomas Gross, Aurora, CO (USA) - Are we reaching the maximum cure rate for Hodgkin lymphomas?
Peter W.M. Johnson, Southampton (UK) - Germinal center in the genesis of lymphomas
Laura Pasqualucci, New York, NY (USA) - Lymphomas in pregnancy
Fedro A. Peccatori, Milan (Italy) - Reappraisal of role of radiation therapy in lymphoma treatment
Lena Specht, Copenhagen (Denmark) - Peripheral T-cell lymphomas
Pier Luigi Zinzani, Bologna (Italy) - Marginal zone lymphomas
Emanuele Zucca, Bellinzona (Switzerland)
The collection of articles written by speakers of the Educational symposia and Meet the Professor sessions represents the content of the Educational Book, published by John Wiley and Sons, Ltd. and distributed onsite to the attendees.
During this session, the highest rated abstracts will be presented by authors and discussed by the world's most renowned lymphoma experts.
The content of the session has been defined on the basis of the evaluation of the submitted abstracts by 17-ICML reviewers.
INTERNATIONAL LYMPHOMA RADIATION ONCOLOGY GROUP (ILROG) WORKSHOPS
These workshops represent an opportunity for interaction and continuous learning not only for radiation oncologists, but also for medical oncologists and haematologists.
Radiation therapy as an immunogenic cell death mechanism in the environment of immunotherapy and adoptive cell therapy.
Moderators: Bouthaina S. Dabaja, Houston, TX (USA) and Joachim Yahalom, New York, NY (USA)
Introducing adoptive cell therapy in the treatment of hematological malignancies has resulted in considering a new role for radiation therapy. We now employ radiation to prime the immune system rather than direct cell killing. Radiation therapy can initiate an antigen-presenting mechanism leading to immunogenic cell death. Our session will give a comprehensive and educational presentation detailing how radiation converses with the immune system and will discuss how introducing radiation therapy will have the potential to further improve the outcome of patients treated with immunotherapy and adoptive cell therapy.
Opportunities in lymphoma radiation therapy today: lower doses, fewer fractions, and real world “Big Data” analyses using machine learning and artificial intelligence.
Moderators: Mary Gospodarowicz, Toronto, ON (CA) and Lena Specht, Copenhagen (Denmark)
Radiation therapy for lymphomas is undergoing dramatic changes, with lower or even ultra-low radiation doses, and with much smaller volumes including only the lymphoma with narrow margins. Hence, the radiation doses and the doses per fraction to normal tissues can be greatly reduced. This makes treatment with fewer but larger fractions possible. COVID prompted testing of these possibilities and the encouraging results of these hypofractionation regimens will be presented. Analyses of big sets of “real world” data will help us to refine lymphoma radiation therapy incorporating multiple outcome objectives, systemic treatments, and patient characteristics.
https://doi.org/10.1182/blood.2020006028
THE BIG DEBATE
MOVING TARGETS IN LYMPHOMA TREATMENT
Chair: Emanuele Zucca, Bellinzona, CH
Satellite symposium organised by the Foundation for the Institute of Oncology Research (IOR)
Supported by sponsorship from Gilead Sciences Europe Ltd. Gilead has had no input into the agenda, speaker selection or content of the presentations used at this event.
DEBATE 1.
Best therapy in aggressive mantle cell lymphoma: Time for frontline chemotherapy-free regimens?
YES - Michael L. Wang, Houston, TX, US
NO - Martin Dreyling, Munich, DE
DEBATE 2.
Towards a cure for relapsing/refractory diffuse large B cell lymphoma: Bispecific antibodies better than CAR-T cells?
YES - Laurie H. Sehn, Vancouver, BC, CA
NO - Gloria Iacoboni, Barcelona, ES
DEBATE 3.
Frontline treatment of advanced Hodgkin lymphoma: Should A+AVD replace PET-driven strategies?
YES - Stephen M. Ansell, Rochester, MN, US
NO - Peter Borchmann, Cologne, DE
IBSA Foundation special forum: "PERSONALIZED THERAPY IN ONCOLOGY"
As in the last 3 editions of ICML, IBSA Foundation organizes a Special Forum accessible to all ICML congress attendees and also the external audience. This is a unique opportunity to explore the topic of personalized therapy in oncology in a debate with international speakers. The focus will be on molecular target therapies as promising therapies tailored to the genetic characteristics of the patient.
Lectures and speakers:
- Organoids model human disease - Hans Clevers, Basel (Switzerland)
- Unconventional approaches to cancer therapy - René Bernards, Amsterdam (Netherland)
- Patient-specific models of multicellular oncogenic competence in metastasis - Arianna Baggiolini, Bellinzona (Switzerland)
Find out more about the event: https://www.ibsafoundation.org/en/activities/forum/personalized-therapy-in-oncology
VI European Lymphoma Canine Network workshop: "FOCUS ON CANINE T CELL LYMPHOMA"
Co-chairs: Luca Aresu, Turin (Italy), Stefano Comazzi, Milan (Italy), Franco Guscetti, Zurich (Switzerland), and Laura Marconato, Bologna (Italy)
The Workshop aims at focusing on some of the hot topics in the field of canine lymphoma, both in terms of comparative and veterinary medicine. This edition will focus on canine T cell lymphomas.
Invited lectures will review the state of the art on pathogenetic, diagnostic and clinical aspects of canine T cell lymphoma underlying its potential comparative use as an animal model. A poster session and some selected free communications will also take place. The workshop will be open to all 17-ICML attendees.
This is a lecture held at the closure of the Scientific Program that summarizes and highlights the themes addressed during the congress.
The participants will receive a series of hints and considerations that will facilitate the identification and understanding of the new knowledge presented and discussed in Lugano.
Martin Dreyling, Munich (Germany)